Abstracts
Important Note Regarding Congress Registration
In order to avail of the 75 EUR credit towards registration, please do NOT register online using the regular system. Details on how to register as a presenting author will be sent by email following receipt of the 75 EUR submission fee.
The Scientific Advisory & Organising Committee (SAOC) of the 29th International Epilepsy Congress encourages all researchers and practitioners to consider contributing to the programme by submitting abstracts for poster or platform presentation.
Rules and Instructions:
The rules and instructions should be followed carefully. Failure to comply with abstract submission rules will result in the abstract not being accepted for review.
*Please note that the rules set out below apply to Poster/Platform abstract submission only. Please note that speakers will not be asked to submit abstracts to illustrate their talks during the 29th IEC..
Submission Rules
Abstract Submission Fee
Content
Online Submission
Submission Rules:
• Abstracts will not be reviewed unless
they are submitted via the congress online submission system before
midnight (GMT), Thursday
31st March 2011. Late abstracts will NOT
be accepted. Abstracts submitted by post, fax or email
will not be considered.
• All abstracts should be written,
submitted and presented in English with a maximum word count of 250
words (not including the abstract title, authors and institutions).
• All correspondence will be sent to the
submitter. It is the responsibility of the submitter to forward any
relevant correspondence to the presenting author.
• Each author is permitted to present
once (not including invited lectures).
• Authors will be notified by email at
the end of May 2011 whether or not their abstract has been approved by
the SAOC. The decision of the SAOC is final and no correspondence will
be entered into.
• Once an abstract has been approved, the
presenting author must register for the entire congress for final
acceptance. Abstracts will only receive final acceptance after the
presenting author has fully registered. An abstract presenter
may not register as a day delegate.
• Abstract presenters should not register
through the regular online registration system as this is only
available to registering congress delegates who did not submit an
abstract. Abstracts presenters will receive an individual link via
email to register for the congress. This link should not be passed to
third parties.
• Presenting authors are expected to
attend the congress. Non-registered authors may be excluded from
publication in the congress final programme and the online Epilepsia
supplement.
• Abstracts accepted and presented at the
congress will be published, subject to editorial review, in an online
supplement of Epilepsia.
• Instructions for both platform and
poster presentations will be available on the congress website. Authors
selected for oral presentations should use Microsoft PowerPoint (PC
Format).
Abstract Submission Fee:
• An abstract submission fee of 75 EUR
must be paid prior to abstract submission. This non-refundable fee will
be deducted from the congress registration fee.
• Abstract submitted without the fee will
not be reviewed by the SAOC.
• Abstract authors whose full
registration will be covered by a third party will be reimbursed the
abstract submission fee after the congress.
• The presenting author name should be
entered when making payment online.
Content:
Abstract submitters should ensure that the version sent is the final one as changes will not be permitted.
Institution information should be provided for all authors and must include the following:
Name of Institution:
City:
State/Province:
Country:
Note: department, division, laboratory, etc. should not be included in the Institution Information
Abstracts should be structured in 4 sections:
1. Purpose
2. Method
3. Results
4. Conclusion
The "Purpose" section should indicate the objectives of the work being presented.
The "Method" section should describe study material or subjects (e.g. number and type of patients), intervention and evaluation procedures.
The "Results" section should summarise the main findings. Wherever possible, give numerical values, including means with SD or SEM, and statistical significance or confidence intervals.
The "Conclusion" section should state briefly the conclusions reached in the work.
• Figures, tables and other illustrations can not be included.
• Where appropriate, the ethics committee that has approved the study should be named.
• If the work was supported by funds provided by a commercial organisation this should be
stated in a short acknowledgment at the end of the abstract. Other sources of funding may be acknowledged in the same way.
• Submission of abstracts describing data that have previously been published in any scientific journal is not permitted.
• Multiple submissions of abstracts describing different components of the same study is
not appropriate. All findings generated from the same study should be included in a single abstract.
• Abstracts containing single case reports will not usually be accepted, unless the report is of outstanding scientific or clinical interest because of the uniqueness of the findings or the sophistication of the investigations.
• Abstracts containing data considered to be insufficiently informative will not be accepted.
• Authors should use a concise title that indicates the content of the abstract. The title should not exceed 240 characters. Abbreviations should be avoided in the title.
• For intervention studies (for example, therapeutic trials), type of design (prospective or retrospective, controlled or uncontrolled, randomised or observational, open vs. single-blind vs. double-blind), dosages, assessment methods and duration of follow-up should be specified.
• Non-proprietary names of drugs must be used throughout. If results are considered to be specific for a given proprietary product (for example, bio-equivalence studies), the non-proprietary name must still be used, followed by the proprietary name and the name of the manufacturers in brackets.
• Abbreviations should be used sparingly. For words that are abbreviated, use the whole term the first time, followed by the standard abbreviation in parenthesis. For anti-epileptic drugs, standard abbreviations are those published in Epilepsia 1993; 34:1151.
• References should be used sparingly. They should be included within the text in brackets. For journals, mention first author "et al" followed by the name of the journal as abbreviated in the Index Medicus, year, volume number and inclusive pages (i.e. Hardus P et al. Epilepsia 2001;42:262-267.). For book chapters, give first author "et al", editor, title, publisher, city of publication, year and inclusive pages (i.e. Levy RH et al. In: Levy RH et al, Antiepileptic Drugs. Lippincott-Raven, 1996;13-30.).
• Submission of an abstract automatically implies acknowledgment that the work described was conducted in accordance with current ethical standards and regulations in biomedical research. Failure to adhere to these standards will result in rejection of the abstract.
Online Submission:
After an abstract payment has been made, submitters will be provided with a link via email which will direct them to the abstract submission system. In order to access the system, submitters will need to create a new account and enter relevant contact information. Please see below.
Once contact information has been input, the submitter will be directed to the ‘Abstracts Overview’ page below. Please click on ‘create’ to submit a new abstract.
Step 1: Insert abstract body which must include topic, title and text; see below.
Step 2: Insert author(s) details along with affiliated institution(s); see below.
Step 3: Preview the abstract before submission; see below.
Step 4: To complete the submission process, please enter the Access Key which was received during the payment process along with the Payment Code and tick the three boxes (see below) if all information is correct.
